230 related articles for article (PubMed ID: 36361758)
21. Total cell-free DNA, carcinoembryonic antigen, and C-reactive protein for assessment of prognosis in patients with metastatic colorectal cancer.
Spindler KG; Demuth C; Sorensen BS; Johansen JS; Nielsen D; Pallisgaard N; Hoegdall E; Pfeiffer P; Vittrup Jensen B
Tumour Biol; 2018 Nov; 40(11):1010428318811207. PubMed ID: 30486767
[TBL] [Abstract][Full Text] [Related]
22. Utility of circulating tumor cells and DNA in the management of advanced colorectal cancer.
Pan X; Zhang X
Future Oncol; 2020 Jun; 16(18):1289-1299. PubMed ID: 32379501
[No Abstract] [Full Text] [Related]
23. Serum CCL20 combined with IL-17A as early diagnostic and prognostic biomarkers for human colorectal cancer.
Wang D; Yuan W; Wang Y; Wu Q; Yang L; Li F; Chen X; Zhang Z; Yu W; Maimela NR; Cao L; Wang D; Wang J; Sun Z; Liu J; Zhang Y
J Transl Med; 2019 Aug; 17(1):253. PubMed ID: 31387598
[TBL] [Abstract][Full Text] [Related]
24. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS
Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403
[TBL] [Abstract][Full Text] [Related]
25. Clinico-pathological correlation of serial measurement of circulating tumor cells in 24 metastatic colorectal cancer patients receiving chemotherapy reveals interpatient heterogeneity correlated with CEA levels but independent of KRAS and BRAF mutation.
Das A; Kunkel M; Joudeh J; Dicker DT; Scicchitano A; Allen JE; Sarwani N; Yang Z; Kaifi J; Zhu J; Liao J; El-Deiry WS
Cancer Biol Ther; 2015; 16(5):709-13. PubMed ID: 25806877
[TBL] [Abstract][Full Text] [Related]
26. Ectopic expression of guanylyl cyclase C in CD34+ progenitor cells in peripheral blood.
Fava TA; Desnoyers R; Schulz S; Park J; Weinberg D; Mitchell E; Waldman SA
J Clin Oncol; 2001 Oct; 19(19):3951-9. PubMed ID: 11579116
[TBL] [Abstract][Full Text] [Related]
27. Association between serum carcinoembryonic antigen and endothelial cell adhesion molecules in colorectal cancer.
Roselli M; Guadagni F; Martini F; Spila A; Mariotti S; D'Alessandro R; Aloe S; Gazzaniga PP; Basili S; Cosimelli M; Ferroni P
Oncology; 2003; 65(2):132-8. PubMed ID: 12931019
[TBL] [Abstract][Full Text] [Related]
28. Detection of recurrent colorectal cancer with high specificity using a reporting threshold for circulating tumor DNA methylated in BCAT1 and IKZF1.
Pedersen SK; Musher BL; LaPointe LC; Tuck MK; Symonds EL; Loayza N; Young GP
Cancer; 2022 May; 128(10):1921-1928. PubMed ID: 35290664
[TBL] [Abstract][Full Text] [Related]
29. Clinical utility of circulating tumor DNA for colorectal cancer.
Osumi H; Shinozaki E; Yamaguchi K; Zembutsu H
Cancer Sci; 2019 Apr; 110(4):1148-1155. PubMed ID: 30742729
[TBL] [Abstract][Full Text] [Related]
30. Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer.
Zhou H; Zhu L; Song J; Wang G; Li P; Li W; Luo P; Sun X; Wu J; Liu Y; Zhu S; Zhang Y
Mol Cancer; 2022 Mar; 21(1):86. PubMed ID: 35337361
[TBL] [Abstract][Full Text] [Related]
31. Circulating tumor cell levels are elevated in colorectal cancer patients with high tumor burden in the liver.
Kaifi JT; Kunkel M; Dicker DT; Joude J; Allen JE; Das A; Zhu J; Yang Z; Sarwani NE; Li G; Staveley-O'Carroll KF; El-Deiry WS
Cancer Biol Ther; 2015; 16(5):690-8. PubMed ID: 25785486
[TBL] [Abstract][Full Text] [Related]
32. Stem cell factor (SCF) and interleukin 3 (IL-3) in the sera of patients with colorectal cancer.
Mroczko B; Szmitkowski M; Wereszczyńska-Siemiatkowska U; Okulczyk B
Dig Dis Sci; 2005 Jun; 50(6):1019-24. PubMed ID: 15986847
[TBL] [Abstract][Full Text] [Related]
33. Increased detection of circulating tumor cells in the blood of colorectal carcinoma patients using two reverse transcription-PCR assays and multiple blood samples.
Wharton RQ; Jonas SK; Glover C; Khan ZA; Klokouzas A; Quinn H; Henry M; Allen-Mersh TG
Clin Cancer Res; 1999 Dec; 5(12):4158-63. PubMed ID: 10632355
[TBL] [Abstract][Full Text] [Related]
34. Detection of circulating tumor cells in peripheral blood of colorectal cancer patients without distant organ metastases.
Liu Y; Qian J; Feng JG; Ju HX; Zhu YP; Feng HY; Li DC
Cell Oncol (Dordr); 2013 Feb; 36(1):43-53. PubMed ID: 23150200
[TBL] [Abstract][Full Text] [Related]
35. Methylated circulating tumor DNA as a biomarker for colorectal cancer diagnosis, prognosis, and prediction.
Nassar FJ; Msheik ZS; Nasr RR; Temraz SN
Clin Epigenetics; 2021 May; 13(1):111. PubMed ID: 34001239
[TBL] [Abstract][Full Text] [Related]
36. Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS).
Benhaim L; Bouché O; Normand C; Didelot A; Mulot C; Le Corre D; Garrigou S; Djadi-Prat J; Wang-Renault SF; Perez-Toralla K; Pekin D; Poulet G; Landi B; Taieb J; Selvy M; Emile JF; Lecomte T; Blons H; Chatellier G; Link DR; Taly V; Laurent-Puig P
Eur J Cancer; 2021 Dec; 159():24-33. PubMed ID: 34731746
[TBL] [Abstract][Full Text] [Related]
37. Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.
Sastre J; Orden V; Martínez A; Bando I; Balbín M; Bellosillo B; Palanca S; Peligros Gomez MI; Mediero B; Llovet P; Moral VM; Viéitez JM; García-Alfonso P; Calle SG; Ortiz-Morales MJ; Salud A; Quintero G; Lopez C; Díaz-Rubio E; Aranda E;
Clin Colorectal Cancer; 2020 Sep; 19(3):e110-e116. PubMed ID: 32278676
[TBL] [Abstract][Full Text] [Related]
38. Dynamic liquid biopsy components as predictive and prognostic biomarkers in colorectal cancer.
Raza A; Khan AQ; Inchakalody VP; Mestiri S; Yoosuf ZSKM; Bedhiafi T; El-Ella DMA; Taib N; Hydrose S; Akbar S; Fernandes Q; Al-Zaidan L; Krishnankutty R; Merhi M; Uddin S; Dermime S
J Exp Clin Cancer Res; 2022 Mar; 41(1):99. PubMed ID: 35292091
[TBL] [Abstract][Full Text] [Related]
39. Correlation of the Pro-Inflammatory Cytokines IL-1β, IL-6, and TNF-α, Inflammatory Markers, and Tumor Markers with the Diagnosis and Prognosis of Colorectal Cancer.
Florescu DN; Boldeanu MV; Șerban RE; Florescu LM; Serbanescu MS; Ionescu M; Streba L; Constantin C; Vere CC
Life (Basel); 2023 Nov; 13(12):. PubMed ID: 38137862
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic and prognostic value of serum IL-23 in colorectal cancer.
Elessawi DF; Alkady MM; Ibrahim IM
Arab J Gastroenterol; 2019 Jun; 20(2):65-68. PubMed ID: 31155425
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
